00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc. , which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company...
20:12 , Jul 7, 2017 |  BC Week In Review  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
18:45 , Jul 6, 2017 |  BC Week In Review  |  Financial News

Acer plans to raise $15.7M ahead of Opexa merger

On July 3, rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) said it will raise $15.7 million from a syndicate of new and existing shareholders led by TVM Capital Life Sciences. Acer is merging with...
22:11 , Jul 3, 2017 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Acer Therapeutics completes venture financing

Acer Therapeutics Inc. , Cambridge, Mass.   Business: Endocrine/Metabolic   Date completed: 2016-05-09   Type: Venture financing   Raised: $8.2 million   Investors: TVM Life Science Ventures; Bukwang Pharmaceutical Co. Ltd.  ...